Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 42 pages | ID: G671CA195738EN
Global Markets Direct

Abstracts

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucose Dependent Insulinotropic Receptor - Drugs In Development, 2022, outlays comprehensive information on the Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - G protein-coupled receptor 119 also known as GPR119 is a G protein-coupled receptor that is encoded by the GPR119 gene. GPR119 is expressed at high concentrations in the pancreas and gastrointestinal tract. GPR119 regulates incretin and insulin hormone secretion. Activation of GPR119 receptor causes a reduction in food intake and weight gain. This target is a potential drug target in treatments for obesity and diabetes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 3, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Gastrointestinal which include indications Type 2 Diabetes, Obesity, Dyslipidemia, Hypoglycemia and Non-Alcoholic Steatohepatitis (NASH).

Furthermore, this report also reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)
• The report reviews Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics and enlists all their major and minor projects
• The report assesses Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction
Global Markets Direct Report Coverage
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Overview
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Companies Involved in Therapeutics Development
CymaBay Therapeutics Inc
Dong-A Socio Holdings Co Ltd
Hyundai Pharma Co Ltd
Japan Tobacco Inc
Mankind Pharma Ltd
Merck & Co Inc
Scohia Pharma Inc
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Drug Profiles
DA-1241 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HOB-047 - Drug Profile
Product Description
Mechanism Of Action
JTP-109192 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MBX-2982 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MKP-10241 - Drug Profile
Product Description
Mechanism Of Action
SCO-094 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize GRP119 for Type 2 Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Dormant Products
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Discontinued Products
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Product Development Milestones
Featured News & Press Releases
Apr 14, 2021: Mankind Pharma seeks approval from CDSCO for treatment of type 2 diabetes, new drug will come in the market
Feb 08, 2021: First-in-class GPR119 agonist of Dong-A ST, DA-1241 improved glucose control in patients with type 2 diabetes in US phase 1b study
Nov 05, 2020: CymaBay announces study to evaluate the potential for GPR119 agonists to prevent hypoglycemia in type 1 diabetes
Aug 11, 2020: SCOHIA initiates a phase 1 study on a dual GLP-1 and GIP receptor agonist (SCO-094)
May 10, 2020: Hyundai Pharm's diabetes drug gets FDA approval for phase 2 clinical trial
Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round
Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982
Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by CymaBay Therapeutics Inc, 2022
Pipeline by Dong-A Socio Holdings Co Ltd, 2022
Pipeline by Hyundai Pharma Co Ltd, 2022
Pipeline by Japan Tobacco Inc, 2022
Pipeline by Mankind Pharma Ltd, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Scohia Pharma Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022